July 6, 2018

Please reload

Recent Posts

FDA Comments on Recently Released Rare Disease Guidance for Industry

September 16, 2015

Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on the recently...

Please reload

Featured Posts

Worldwide orphan drug sales forecast to total $178bn in 2020

November 5, 2015

EvaluatePharma has just released their Orphan Drug Report 2015.  This free report contains tons of great information on the current state of the market.  A few highlights below:


- Median cost per patient differential is 13.8 times higher for orphan drugs compared to non-orphan

- Phase III orphan drug development costs half that of non-orphan but Phase III drug development

- Worldwide orphan drug sales forecast to total $178bn (CAGR 2015 to 2020: +11.7%); nearly double the overall prescription market growth


To download a full copy of this free report, please click on the following link: http://www.evaluategroup.com/public/reports/EvaluatePharma-Orphan-Drug-Report-2015.aspx#anchor

Please reload

Patagonia Pharmaceuticals, LLC

50 Tice Blvd, Suite A26

Woodcliff Lake, NJ 07677

For more info: info@patagoniarx.com

© 2019 by Patagonia Pharmaceuticals, LLC